Free Trial

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives $83.25 Average PT from Analysts

ANI Pharmaceuticals logo with Medical background

Key Points

  • ANI Pharmaceuticals, Inc. has received a consensus rating of "Buy" from nine ratings firms, with an average 12-month target price of $83.25.
  • The company reported $1.80 EPS for the last quarter, exceeding estimates, along with a revenue increase of 53.2% year-over-year.
  • Insider trading activity showed senior vice president Ori Gutwerg sold 881 shares valued at approximately $52,921, indicating a 0.97% decrease in ownership.
  • Need better tools to track ANI Pharmaceuticals? Try 5 Weeks of MarketBeat All Access for $5. Start Portfolio Tracking Now.

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) have been assigned an average recommendation of "Buy" from the nine analysts that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $84.75.

Several equities research analysts have recently issued reports on the stock. Piper Sandler reaffirmed an "overweight" rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Friday. Truist Financial lifted their price objective on shares of ANI Pharmaceuticals from $65.00 to $77.00 and gave the stock a "hold" rating in a research report on Monday. Wall Street Zen cut shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Thursday, April 24th. HC Wainwright reaffirmed a "buy" rating and set a $93.00 price objective (up from $84.00) on shares of ANI Pharmaceuticals in a research report on Friday. Finally, Guggenheim reissued a "buy" rating and issued a $86.00 price target on shares of ANI Pharmaceuticals in a research report on Monday, May 12th.

View Our Latest Report on ANIP

ANI Pharmaceuticals Stock Up 4.2%

ANIP stock traded up $3.40 during midday trading on Friday, hitting $84.88. The company's stock had a trading volume of 1,671,238 shares, compared to its average volume of 347,991. The company has a quick ratio of 1.96, a current ratio of 2.54 and a debt-to-equity ratio of 1.39. ANI Pharmaceuticals has a 52-week low of $52.50 and a 52-week high of $87.95. The firm has a market capitalization of $1.84 billion, a P/E ratio of -110.23 and a beta of 0.61. The firm has a 50-day simple moving average of $65.19 and a 200-day simple moving average of $63.90.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its quarterly earnings results on Friday, August 8th. The specialty pharmaceutical company reported $1.80 EPS for the quarter, beating the consensus estimate of $1.42 by $0.38. ANI Pharmaceuticals had a negative net margin of 1.37% and a positive return on equity of 25.03%. The company had revenue of $211.37 million during the quarter, compared to analysts' expectations of $187.18 million. During the same quarter last year, the company posted $1.02 EPS. The firm's revenue was up 53.2% compared to the same quarter last year. As a group, equities analysts forecast that ANI Pharmaceuticals will post 3.86 EPS for the current year.

Insider Activity

In other news, insider Christopher Mutz sold 4,000 shares of the company's stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $60.45, for a total value of $241,800.00. Following the completion of the sale, the insider directly owned 107,317 shares of the company's stock, valued at approximately $6,487,312.65. This represents a 3.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Meredith Cook sold 400 shares of the company's stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $64.88, for a total transaction of $25,952.00. Following the completion of the sale, the vice president directly owned 78,945 shares of the company's stock, valued at $5,121,951.60. The trade was a 0.50% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 5,681 shares of company stock valued at $345,222. Insiders own 11.10% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Principal Financial Group Inc. grew its position in ANI Pharmaceuticals by 68.3% during the first quarter. Principal Financial Group Inc. now owns 157,798 shares of the specialty pharmaceutical company's stock worth $10,565,000 after buying an additional 64,021 shares during the period. Allspring Global Investments Holdings LLC grew its position in ANI Pharmaceuticals by 53.3% during the first quarter. Allspring Global Investments Holdings LLC now owns 8,949 shares of the specialty pharmaceutical company's stock worth $599,000 after buying an additional 3,112 shares during the period. GAMMA Investing LLC grew its position in ANI Pharmaceuticals by 163.8% during the first quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company's stock worth $95,000 after buying an additional 881 shares during the period. Stifel Financial Corp grew its position in shares of ANI Pharmaceuticals by 20.4% in the fourth quarter. Stifel Financial Corp now owns 8,424 shares of the specialty pharmaceutical company's stock valued at $466,000 after purchasing an additional 1,425 shares during the last quarter. Finally, Northern Trust Corp grew its position in shares of ANI Pharmaceuticals by 9.0% in the fourth quarter. Northern Trust Corp now owns 204,345 shares of the specialty pharmaceutical company's stock valued at $11,296,000 after purchasing an additional 16,820 shares during the last quarter. 76.05% of the stock is currently owned by institutional investors and hedge funds.

ANI Pharmaceuticals Company Profile

(Get Free Report)

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.

Further Reading

Analyst Recommendations for ANI Pharmaceuticals (NASDAQ:ANIP)

Should You Invest $1,000 in ANI Pharmaceuticals Right Now?

Before you consider ANI Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ANI Pharmaceuticals wasn't on the list.

While ANI Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Growth Stocks That Could Pop Before Summer Ends
3 Buy-the-Dip Stocks Poised to Rebound Soon
Quantum Boom: 3 Strong Picks with Lower Risk

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines